From Nasdaq: 2025-05-02 17:45:00

Novavax (NVAX) closed at $6.41, unchanged from the previous session, lagging behind the S&P 500 and Nasdaq gains. The vaccine maker’s shares rose 14.46% in the past month, with an upcoming earnings report on May 8, 2025, expected to show an EPS increase of 118.1% and a revenue decline of 23.47%.

Analysts forecast Novavax’s full-year earnings at $0.63 per share and revenue at $536.24 million, with recent estimates revisions indicating positivity towards the company’s operations. With a Zacks Rank of #3 (Hold) and a Forward P/E ratio of 10.2, Novavax trades at a discount to its industry average.

The Medical – Biomedical and Genetics industry, part of the Medical sector, has an average PEG ratio of 1.34, while Novavax’s PEG ratio stands at 0.24. The industry ranks in the top 35% of all industries, showing potential for growth. Investors can monitor these metrics on Zacks.com for future trading sessions.

Zacks experts have identified 5 stocks with the potential to double in 2024, handpicked as favorites with previous recommendations soaring up to +673.0%. These stocks, flying under Wall Street radar, offer an opportunity for investors to get in early on potential high-growth opportunities. To learn more, visit Zacks.com for the latest stock recommendations.



Read more at Nasdaq: Novavax (NVAX) Flat As Market Gains: What You Should Know